Agenus data at sitc 2022 highlight durable responses of botensilimab / balstilimab combination in nine different treatment-resistant cancers

Lexington, mass., nov. 14, 2022 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the company's phase 1 study of botensilimab (fc-enhanced anti-ctla-4) and balstilimab (anti-pd-1) in patients with treatment-resistant tumors, including mss-crc, ovarian, sarcoma and nsclc. the data presented represents four of the most mature data sets from the nine cancer types where responses have been observed to date. the data was presented at a plenary session at the society for immunotherapy of cancer (sitc) annual meeting and a company-hosted r&d event.
AGEN Ratings Summary
AGEN Quant Ranking